The proprietary engine
Patented LBX242, engineered to withstand resistance.
A proprietary composition engineered to withstand the evolution of bacterial resistance at the molecular source.
01
Targeted structural disruption
LBX242 is structurally disruptive in a way that target pathogens cannot route around.
02
No observed evolutionary resistance
Across two decades of independent study, no resistance has been observed — a property without parallel among conventional antibiotics.
03
Patented compositional structure
The engine is not a single molecule. It is a patented composition, protecting both the botanical matrix and the synthetic derivative.
De-risking matrix
Two parallel assets.
Two independently patented compositions — one botanical, one synthetic — multiply delivery options and de-risk capital across parallel clinical pathways. Both deploy the same patented LBX242 composition.
Asset 01 · Botanical matrix
LBX242
- Classification
- Botanical matrix
- Composition
- A patented botanical matrix.
- Strategic advantage
- Three decades of broad global human use of the natural composition (beginning in 1996), qualifying the 505(b)(1) botanical pathway.
Asset 02 · Small molecule
LBX242
- Classification
- Synthetic small molecule
- Composition
- Synthetic LBX242 derivative, engineered for precision delivery.
- Strategic advantage
- Highly targeted bio-defense delivery mechanisms, qualifying the QIDP / LPAD synthetic pathway.
Route 01
The botanical express lane.
The 505(b)(1) botanical pathway, paired with three decades of broad global human use, delivers the speed and capital efficiency of a 505(b)(2) application — bypassing standard Phase 1 delays.
Estimated savings exceed ten million dollars and more than two years of clinical-trial overhead.
- 01
FDA Botanical Guidance
A codified regulatory framework for novel botanical therapeutics, distinct from the standard synthetic-drug pathway.
- 02
Three decades of human use
The composition has three decades of broad global human use, beginning in 1996, satisfying the prior-use requirement.
- 03
Express-lane equivalence
Together, these qualify LBX242 for the speed and capital profile of a 505(b)(2) application.
- 04
Precedent: Arikayce
Arikayce (Insmed Inc.) — an antibiotic with a nanocarrier for lung delivery — successfully bypassed Phase 1 trials under the same class of FDA framework.
Route 02
The synthetic fast track.
Two federal antimicrobial-resistance frameworks compound for LBX242: QIDP under the GAIN Act grants five years of additional market exclusivity with automatic Fast Track status; the LPAD pathway scales trial burden to a limited, highly resistant patient population.
Together, these compress the approval timeline while preserving full commercial exclusivity.
QIDP · GAIN Act
+5 years exclusivity
Qualified Infectious Disease Product designation under the GAIN Act secures five additional years of market exclusivity on top of the base term, and automatically unlocks Fast Track review.
LPAD pathway
Limited Population Approval
Limited Population for Antimicrobial Drugs scales the statistical threshold: efficacy is demonstrated on a small, highly resistant cohort, compressing timeline and cost.
Convergence
Strategic asymmetry.
Biological rationale fused with expedited FDA pathways creates a highly asymmetric profile. Three vectors compound around a single patented engine.
01
Deep biological rationale
LBX242 acts on target pathogens through mechanisms not addressed by known resistance pathways.
02
Regulatory fast-tracking
The GAIN Act, LPAD, and Botanical Guidance jointly reduce years of clinical delay and mitigate trial cost.
03
Capital efficiency
Parallel routes mean early funding achieves compounding milestones, de-risking sequential capital raises.
Capital strategy
A $500K foundation catalyst.
A foundation catalyst of five hundred thousand dollars de-risks the subsequent one-point-five-million-dollar raise, satisfying baseline FDA toxicity requirements prior to Series A.
Efficacy validation
$60–80K · MicroChem Labs
In-vitro testing against the World Health Organization list of multi-drug-resistant bacteria, establishing a disease-agnostic efficacy profile.
Safety validation
$380–420K · Charles River
A formal preclinical toxicology program at Charles River Laboratories to satisfy the FDA prerequisite dossier for IND progression.
The catalyst — a $500,000 foundation — de-risks the next $1,500,000: a $2.0 million raise that protects shareholder value through Series A.
Gateway
Request the full platform briefing.
The clinical data deck, regulatory strategy, and mechanism-of-action briefing are available to qualified scientific, regulatory, and investment parties.